HOME > Drug Approval & Reimbursement in 2024
Drug Approval & Reimbursement in 2024
-
Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
-
Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
-
Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
-
Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
-
Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
-
Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
-
Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
-
Japan Approves Novartis’ Fabhalta, Lilly’s Jaypirca, and Lots More
June 25, 2024
-
Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
-
Japan to Increase Reimbursement Rounds to 7 Times a Year from 2025
May 16, 2024
-
Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
-
Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
Shionogi’s COVID Pill Xocova Lands Standard Approval in Japan
March 5, 2024
-
Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
-
Japan Approves Pfizer’s RSV Jab, Ultragenyx’s Evkeeza, and More
January 19, 2024
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…